Vet World   Vol.12   February-2019  Article-19

Research Article

Veterinary World, 12(2): 309-315

https://doi.org/10.14202/vetworld.2019.309-315

Antiretroviral activity of Pterois volitans (red lionfish) venom in the early development of human immunodeficiency virus/acquired immunodeficiency syndrome antiretroviral alternative source

Andy Noorsaman Sommeng1, R. Muhammad Yusuf Arya1, Mikael Januardi Ginting2, Diah Kartika Pratami3, Heri Hermansyah1, Muhamad Sahlan1,4, and Anondho Wijanarko1
1. Department of Chemical Engineering, Faculty of Engineering, Universitas Indonesia, Indonesia.
2. Marine Science Postgraduate Program, Faculty of Mathematics and Natural Sciences, Universitas Indonesia, Indonesia.
3. Laboratory of Pharmacognosy and Phytochemistry, Faculty of Pharmacy, Pancasila University, Indonesia.
4. Research Center for Biomedical Engineering, Faculty of Engineering, Universitas Indonesia, Indonesia.

Background and Aim: This study aimed to investigate the antiviral activity of Pterois volitans phospholipase A2 (PV-PLA2) from Indonesia to human immunodeficiency virus (HIV).

Materials and Methods: Fresh venomous fin parts of wild PV specimens were collected from Java Sea waters. Then, it washed using phosphate buffer pH 7.0 and immersed in phosphate buffer pH 7.0 0.01 m containing CaCl2 0.001 m for 24 h. The immersed fin then allowed for extraction process by sonicating for 2×8 min with 80% pulse and 20 kHz output with temperature controlling to avoid denaturation. The crude venom (CV) extracted from the fin is allowed for purification by 80% ethanol (ET) precipitation and ammonium sulfate fractionation method. The purified PV-PLA2 then analyzed using Lowry's method, Marinette's method, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and 3-(4, 5-dimethyl thiazol-2yl)-2, 5-diphenyl tetrazolium bromide assay. After determining the purest and safest sample of six samples analyzed, the chosen sample then tested into simian retrovirus-2 (SRV2)-A549 culture (48×104 cells/mL at 1-4 ppm), and compared to the CV sample (1-4 ppm) and lamivudine (100 ppm). The culture then is analyzed using a quantitative real time-polymerase chain reaction to find out the copy number of SRV-2 virus in each culture.

Results: The protein's activity, concentration, and purity analysis revealed that the PV-PLA2 purified using ammonium sulfate fractionation has the highest activity (1.81 times higher than the CV at 80% fractionation) and has higher purity than the sample from ET fractionation. The testing of the sample purified using ammonium sulfate fractionation at 80% saturation level shown that it has a 97.78% inhibition level toward SRV2-A549 culture at 4 ppm. However, in comparison to lamivudine which has 99.55% inhibition level at 100 ppm, it needs much lower concentration to achieve the same result.

Conclusion: The significant inhibition of SRV2-A549 culture shown that the PV-PLA2 extracted from PV venom has the potential to become anti-HIV substances. It would be worthwhile to further evaluate the antiretroviral activity of PV-PLA2 in the in vivo studies. Keywords: antiretrovirus, lamivudine, phospholipase A2, Pterois volitans, simian retrovirus serotype 2.

Keywords: antiretrovirus, lamivudine, phospholipase A2, Pterois volitans, simian retrovirus serotype 2.

How to cite this article: Sommeng AN, Arya RMY, Ginting MJ, Pratami DK, Hermansyah H, Sahlan M, Wijanarko A (2019) Antiretroviral activity of Pterois volitans (Red Lionfish) venom in the early development of human immunodeficiency virus/acquired immunodeficiency syndrome antiretroviral alternative source, Veterinary World, 12(2): 309-315.

Received: 16-09-2018  Accepted: 02-01-2019     Published online: 23-02-2019

Corresponding author: Muhamad Sahlan   E-mail: sahlan@che.ui.ac.id

DOI: 10.14202/vetworld.2019.309-315

Copyright: Sommeng, et al. This article is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http:// creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.